Trial shows 98% of recovered HER2 breast cancer patients maintain heart function after stopping meds

The study enrolled women in their 40s and 50s whose ejection fraction had declined during trastuzumab or similar HER2 therapy but later recovered to above 50%. Participants were randomized to continued therapy or supervised withdrawal with monthly echocardiographic and biomarker surveillance for 12 months. Only one patient in the withdrawal arm showed a clinically relevant drop, while quality-of-life scores improved modestly in those off medication. Long-term follow-up continues to five years. Context from prior observational registries indicates that roughly 10-15% of HER2-treated patients develop cardiotoxicity, yet current guidelines extrapolate lifelong therapy from non-cancer heart-failure cohorts without testing de-escalation. This trial directly challenges that extrapolation by demonstrating recovery is durable under close monitoring. It also highlights survivorship trade-offs: fatigue, bradycardia, and pill burden affect adherence to endocrine therapy that confers larger absolute survival gains. Next steps require a larger multicenter RCT powered for clinical events rather than surrogate echocardiographic stability, plus integration of strain imaging and circulating biomarkers to refine withdrawal criteria. Regulators may need to update labeling for ACE inhibitors and beta-blockers in this specific population if five-year data confirm low relapse rates.